Payment overview · 2025
General Payments
$2,292.51
109 reported records · 21 companies
Healthcare provider profile · identity verified
Scott D Parker, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease · HUNTSVILLE, AL · NPI 1992716120
Verified facts
What the public records show
CMS Open Payments records show Scott D Parker, MD received $2,292.51 in general payments during 2025 across 109 reported records.
Insmed, Inc. accounted for 14.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arikayce, Dalvance, Dovato.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALVANCE as an associated drug or biological on 20326 records involving 8863 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Dalvance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Descovy by this doctor in 2024.
Insmed, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Arikayce as an associated drug or biological on 32500 records involving 8305 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arikayce by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insmed, Inc. | Unresolved — no canonical attribution shown | $332.04 | 14.5% | 17 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $294.29 | 12.8% | 14 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $271.59 | 11.8% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $242.70 | 10.6% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $177.68 | 7.8% | 10 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $159.84 | 7.0% | 21 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $158.48 | 6.9% | 6 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $106.41 | 4.6% | 4 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $101.98 | 4.5% | 4 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $89.49 | 3.9% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $66.06 | 2.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.90 | 2.4% | 2 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $41.82 | 1.8% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $39.76 | 1.7% | 2 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.20 | 1.5% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $24.26 | 1.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $23.89 | 1.0% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $20.12 | 0.9% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $18.19 | 0.8% | 1 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $17.73 | 0.8% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $16.08 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,013.09 | 89 |
| Education | $279.42 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $314.66 | 16 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $284.00 | 13 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $271.59 | 8 | 2025 |
Source payment records
|
|||||
| VIBATIV Normalized: vibativ |
Drug | Cumberland Pharmaceuticals, Inc. | $159.11 | 20 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $155.83 | 9 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $138.83 | 8 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $113.48 | 6 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $106.83 | 4 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $106.41 | 4 | 2025 |
Source payment records
|
|||||
| Orbactiv Normalized: orbactiv |
Drug | Melinta Therapeutics, LLC | $106.41 | 4 | 2025 |
Source payment records
|
|||||
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $106.41 | 4 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $101.98 | 4 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $101.98 | 4 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $99.34 | 5 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $91.97 | 6 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $66.06 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $65.59 | 2 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $54.90 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $54.90 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $54.90 | 2 | 2025 |
Source payment records
|
|||||
| Cresemba Normalized: cresemba |
Drug | Astellas Pharma US Inc | $53.71 | 4 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $51.65 | 2 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ Normalized: aquacel ag |
Device | ConvaTec Inc. | $41.82 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $39.76 | 2 | 2025 |
Source payment records
|
|||||
| REBYOTA Normalized: rebyota |
Biological | Ferring Pharmaceuticals Inc. | $35.20 | 2 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| URGOCLEAN AG Normalized: urgoclean ag |
Device | Urgo Medical North America, LLC | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $10.29 | 1 | 2025 |
Source payment records
|
|||||
| CALDOLOR Normalized: caldolor |
Drug | Cumberland Pharmaceuticals, Inc. | $0.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Arikayce arikayce |
2025 | Arikayce | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DALVANCE dalvance |
2025 | Dalvance | 2024 | 193 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | DALVANCE open payments reported associated product |
CMS Open Payments — General Payments 20326 supporting records · 8863 recipient NPIs · example record 1201352826 |
Dalvance · 2024 Exact normalized brand match · 1 Part D row |
193 | 59 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Insmed, Inc. Exact reporting entity; no affiliate inference |
2025 | Arikayce open payments reported associated product |
CMS Open Payments — General Payments 32500 supporting records · 8305 recipient NPIs · example record 1186254431 |
Arikayce · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Doxycycline Hyclate | Doxycycline Hyclate | 233 | 99 |
| Levofloxacin | Levofloxacin | 221 | 101 |
| Dalvance | Dalbavancin Hcl | 193 | 59 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 167 | 79 |
| Cephalexin | Cephalexin | 166 | 61 |
| Sodium Chloride | 0.9 % Sodium Chloride | 104 | 23 |
| Ertapenem | Ertapenem Sodium | 99 | 18 |
| Dextrose In Water | Dextrose 5 % In Water | 85 | 31 |
| Clindamycin Hcl | Clindamycin Hcl | 84 | 38 |
| Cefepime Hcl | Cefepime Hcl | 72 | 13 |
| Rifampin | Rifampin | 72 | 21 |
| Fluconazole | Fluconazole | 67 | 40 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 65 | 36 |
| Daptomycin | Daptomycin | 64 | 15 |
| Azithromycin | Azithromycin | 62 | 11 |
| Ethambutol Hcl | Ethambutol Hcl | 41 | suppressed |
| Meropenem | Meropenem | 41 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 40 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 14 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 32 | 29 |
| Vancomycin Hcl | Vancomycin Hcl | 32 | suppressed |
| Gabapentin | Gabapentin | 30 | 12 |
| Amoxicillin | Amoxicillin | 29 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 29 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 26 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 11 |
| Prednisone | Prednisone | 17 | suppressed |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Tivicay | Dolutegravir Sodium | 15 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Darunavir | Darunavir | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ritonavir | Ritonavir | 12 | suppressed |
| Abacavir | Abacavir Sulfate | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,292.51 · 109 records | Insmed, Inc. | AQUACEL AG+, AVYCAZ, Arikayce, Brinsupri, CABENUVA, CALDOLOR, CAPVAXIVE, COLLAGENASE SANTYL, CUTAQUIG, Cresemba, DALVANCE, DOVATO, EGRIFTA, EMBLAVEO, Flexitouch Plus, Hizentra, Kerecis GraftGuide, Kerecis SurgiClose, Kimyrsa, Nimbl, OCTAGAM IMMUNE GLOBULIN (HUMAN), Orbactiv, PANZYGA, PIFELTRO, PURAPLY WOUND MATRIX, REBYOTA, Rezzayo, TEFLARO, TROGARZO, URGOCLEAN AG, VIBATIV, VOWST, Xembify, ZERBAXA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arikayce play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error